Wei Yin

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Bipolar Disorder

Top Venues

Clinical and translational science

Drug metabolism and disposition: the biological fate of chemicals

British journal of clinical pharmacology

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Yin, Axel Facius, Mahnaz Asgharnejad, Gëzim Lahu, Majid Vakilynejad
Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies. Clinical and translational science 17 (3) (2024)
Wei Yin, Cheng Dong, Annette Stevenson, Valerie Lloyd, Marco Petrillo, Mike Baratta, Tom Hui, Steve Han
Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers. Drug metabolism and disposition: the biological fate of chemicals 52 (3) (2024)
Wei Yin, Axel Facius, Mahnaz Asgharnejad, Gëzim Lahu, Majid Vakilynejad
Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies. Clinical and translational science 17 (3) (2024)
Wei Yin, Pranab Mitra, Veronique Copalu, Thomas C Marbury, Juan Carlos Rondon, Eric J Lawitz, Valerie Lloyd, Mike Baratta, Mahnaz Asgharnejad, Tom Hui, Yasir Khan
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function. Pharmacology research & perspectives 12 (4) (2024)
Wei Yin, Pranab Mitra, Veronique Copalu, Thomas C Marbury, Juan Carlos Rondon, Eric J Lawitz, Valerie Lloyd, Mike Baratta, Mahnaz Asgharnejad, Tom Hui, Yasir Khan
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function. Pharmacology research & perspectives 12 (4) (2024)
Wei Yin, Cheng Dong, Annette Stevenson, Valerie Lloyd, Marco Petrillo, Mike Baratta, Tom Hui, Steve Han
Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers. Drug metabolism and disposition: the biological fate of chemicals 52 (3) (2024)
Wei Yin, Axel Facius, Mahnaz Asgharnejad, Gëzim Lahu, Majid Vakilynejad
Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies. Clinical and translational science 17 (3) (2024)
Wei Yin, Cheng Dong, Annette Stevenson, Valerie Lloyd, Marco Petrillo, Mike Baratta, Tom Hui, Steve Han
Effects of Strong Inhibition of CYP3A and UGT1A9 and Strong Induction of CYP3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers. Drug metabolism and disposition: the biological fate of chemicals (2023)
Wei Yin, T Eric Ballard, Sean Xiaochun Zhu, Samuel Hsiao, Hao Chen, Yuexian Li, Swapan K Chowdhury, Annette Stevenson, Tom Hui, Allen Hunt, Mahnaz Asgharnejad, Steve Han
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers. British journal of clinical pharmacology (2023)
Wei Yin, Axel Facius, Thomas Wagner, Max Tsai, Mahnaz Asgharnejad, Gëzim Lahu, Majid Vakilynejad
Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults. Clinical and translational science (2023)
Wei Yin, David Han, Polyna Khudyakov, Rhett Behrje, Joel Posener, Antonio Laurenza, Dimitrios Arkilo
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia. British journal of clinical pharmacology 88 (8) (2022)
Wei Yin, Dimitrios Arkilo, Polyna Khudyakov, Jim Hazel, Saurabh Gupta, Maria S Quinton, Jie Lin, Deborah S Hartman, Martin M Bednar, Laura Rosen, Jens R Wendland
Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A. British journal of clinical pharmacology (2021)